Tirzepatide Cost 2026: Brand vs Compounded vs Telehealth

In 2026, brand tirzepatide (Zepbound, Mounjaro) lists near $1,000–$1,080 per 28-day supply, but Eli Lilly's LillyDirect self-pay vials start at $299/month for the 2.5 mg dose, $399/month for 5 mg, and $449/month for higher doses under the Self Pay Journey Program. Compounded tirzepatide is now sharply restricted after the FDA declared the shortage resolved. This guide compares every pricing pathway.

Tirzepatide cost at a glance

• Brand list price (Zepbound): ~$1,086 per 28-day supply before discounts
• Brand list price (Mounjaro): ~$1,080 per 28-day fill before discounts
• LillyDirect self-pay vials: $299/month (2.5 mg starter); $399/month (5 mg); $449/month for 7.5–15 mg under the Self Pay Journey Program
• Commercial insurance with coverage: as low as $25/month via Lilly savings card
• Medicare GLP-1 Bridge (from July 1, 2026): $50 copay per 30-day supply for eligible beneficiaries (Zepbound KwikPen only)
• Compounded tirzepatide: now restricted — broad 503A/503B compounding ended in 2025 after the FDA declared the shortage resolved
• Telehealth compounded pricing (where still legally available): roughly $125–$400/month, narrowing fast under FDA enforcement

What is tirzepatide and why does its cost vary so much?

Tirzepatide is a once-weekly injectable peptide that activates two incretin receptors, GIP and GLP-1. Eli Lilly sells it under two brand names: Mounjaro, approved for type 2 diabetes, and Zepbound, approved for chronic weight management. Both contain the same active molecule, but they are priced, covered, and discounted differently.

Tirzepatide's cost varies for three reasons. First, the channel matters: a retail pharmacy fill, a manufacturer self-pay vial, and an insurance copay are three different prices for the same drug. Second, insurance status swings the out-of-pocket figure from roughly $25 to well over $1,000. Third, the legal landscape for compounded copies changed in 2025–2026, removing what had been the cheapest pathway for many people. In a 72-week head-to-head trial, tirzepatide produced 20.2% mean body-weight reduction versus 13.7% for semaglutide, which helps explain sustained demand and limited price competition (Aronne et al., 2025, N Engl J Med).

For a deeper look at the molecule itself, see our tirzepatide complete guide. For how it stacks up against the other leading incretin, see semaglutide vs tirzepatide.

How much does brand-name tirzepatide cost in 2026?

Brand-name tirzepatide carries a high list price, but very few people pay the full list. Here is how the brand channel breaks down.

The list price is the manufacturer's pre-discount sticker. Most insured patients never pay it. With a commercial plan that covers tirzepatide, Lilly's savings card can bring the monthly cost to as little as $25. With a commercial plan that does not cover it, a separate savings tier can lower a fill to roughly $499. People with government insurance — Medicare, Medicaid, TRICARE, VA — generally cannot use manufacturer savings cards.

A meaningful change for 2026: the Medicare GLP-1 Bridge, a temporary CMS demonstration, will give eligible Part D beneficiaries access to certain GLP-1 weight medications — including the Zepbound KwikPen — for a $50 copay per 30-day supply, running July 1, 2026 through December 31, 2027 (CMS, 2026). The $50 copay does not count toward the Part D deductible or out-of-pocket cap.

How much do LillyDirect self-pay tirzepatide vials cost?

LillyDirect is Eli Lilly's direct-to-patient pharmacy. Its single-dose vials are the most affordable regulated, brand-authentic tirzepatide pathway in 2026 for cash-pay patients. A valid prescription is still required.

• 2.5 mg (starter): $299/month
• 5 mg: $399/month
• 7.5 mg, 10 mg, 12.5 mg, 15 mg: $449/month under the Self Pay Journey Program

On December 1, 2025, Eli Lilly lowered the price of Zepbound single-dose vials sold through LillyDirect: the 2.5 mg starter dose to $299/month (down from $349), the 5 mg dose to $399/month (down from $499), and the 7.5 mg through 15 mg doses to $449/month (down from $499) for eligible adults with obesity and a valid prescription, regardless of insurance (Eli Lilly and Company, 2025). The $449 ceiling on the four highest doses is tied to the Self Pay Journey Program, an offer that begins February 23, 2026 and requires completing each refill purchase within 45 days of the prior delivery to maintain the discounted rate. Outside that program, the regular non-program prices are $499 for 7.5 mg and $699 for 10 mg, 12.5 mg, and 15 mg (Eli Lilly and Company, 2025).

Because the vials are self-administered with a syringe rather than a prefilled pen, they cost less than the pen presentations. This is brand-name tirzepatide — not a compounded copy.

How much does compounded tirzepatide cost, and is it still available?

Compounded tirzepatide was historically the cheapest route, often $150–$400/month through telehealth. That pathway is now sharply restricted, and price is no longer the main consideration — legality is.

Compounding pharmacies were permitted to make copies of tirzepatide only while it sat on the FDA drug shortage list. The FDA determined the tirzepatide shortage was resolved and then ended enforcement discretion: for state-licensed 503A pharmacies as of February 18, 2025, and for 503B outsourcing facilities as of March 19, 2025 (FDA, 2025). A federal district court declined to block the FDA's position in 2025, and the matter has been on appeal.

The restriction tightened further in 2026. On April 30, 2026, the FDA proposed excluding tirzepatide, semaglutide, and liraglutide from the 503B bulks list, stating it had not identified a clinical need for outsourcing facilities to compound them from bulk drug substances (FDA, 2026). Separately, the FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 to evaluate a set of unapproved research peptides for the 503A affirmative list — a process distinct from the approved GLP-1 drugs, but a signal of how actively the agency is policing the compounded-peptide space (FDA, 2026).

What this means for cost in 2026:

• A narrow 503A exception can still apply for an individual patient with a documented, prescriber-justified clinical need (for example, an allergy to an inactive ingredient) — not for cost savings alone.
• Where compounded tirzepatide is still lawfully dispensed, telehealth pricing has ranged roughly $125–$400/month, but availability is contracting as enforcement expands and several large telehealth brands have exited compounding.
• Compounded products are not FDA-approved, are not reviewed for the same manufacturing standards as brand tirzepatide, and have been the subject of FDA warning letters. Quality, dosing accuracy, and sourcing vary by pharmacy.

Before considering any compounded or non-standard source, review our peptide sourcing guide and consult your healthcare provider. Legal status varies by jurisdiction; consult a lawyer for binding advice.

Brand vs compounded vs telehealth: which is cheapest in 2026?

There is no single "cheapest" answer — it depends on insurance and eligibility. A rough ranking for a typical patient:

1. Commercial insurance that covers tirzepatide → as low as $25/month (savings card). Cheapest when available.
2. Medicare GLP-1 Bridge (eligible beneficiaries, from July 1, 2026) → $50/month for the Zepbound KwikPen.
3. LillyDirect self-pay vials → $299/month starter, $399/month for 5 mg, $449/month for 7.5–15 mg under the Self Pay Journey Program. Best regulated cash-pay route.
4. Compounded via 503A (narrow eligibility) → variable, historically $125–$400/month, but legally restricted and quality-variable.
5. Brand list price, fully uninsured, no program → ~$1,000+/month. The figure to avoid.

The headline shift since 2024 is that the gap between brand and compounded has narrowed: brand self-pay fell toward $299–$449 while compounded access shrank. For many cash-pay patients, the regulated LillyDirect vial is now both safer and competitively priced. Decisions about therapy, dose, and source should be made with a licensed clinician. Consult your healthcare provider before starting any peptide protocol.

Frequently asked questions

Q: How much does tirzepatide cost per month in 2026? A: It depends entirely on your pathway. With commercial insurance that covers it, tirzepatide can cost as little as $25/month using Eli Lilly's savings card. Without insurance, LillyDirect self-pay vials run $299/month for the 2.5 mg starter dose, $399/month for 5 mg, and $449/month for higher doses under the Self Pay Journey Program. The brand list price for Zepbound or Mounjaro is roughly $1,080–$1,086 per 28-day supply before any discount, which few people actually pay. Eligible Medicare beneficiaries may pay $50/month through the GLP-1 Bridge starting July 1, 2026. Costs change frequently; confirm current pricing with the pharmacy and your provider.

Q: Is Zepbound or Mounjaro cheaper? A: Zepbound and Mounjaro contain the same active ingredient, tirzepatide, at similar list prices (around $1,080–$1,086 per 28-day supply). The practical cost difference comes from coverage and discounts, not the drug. Mounjaro is approved for type 2 diabetes and is more often covered by insurance for that indication; Zepbound is approved for weight management and has the LillyDirect self-pay vial program starting at $299/month. Which is cheaper for you depends on your diagnosis, insurance, and eligibility for manufacturer programs. Discuss the right product with your healthcare provider.

Q: Why is compounded tirzepatide so much harder to get in 2026? A: Compounding pharmacies could legally copy tirzepatide only while it was on the FDA drug shortage list. The FDA declared the shortage resolved and ended enforcement discretion for 503A pharmacies on February 18, 2025 and for 503B outsourcing facilities on March 19, 2025. In April 2026 the FDA also proposed excluding tirzepatide from the 503B bulks list. A narrow 503A exception remains for individual patients with a documented clinical need, but not for cost savings. As a result, broad, low-cost compounded access has largely ended. Legal status varies by jurisdiction; consult a lawyer for binding advice.

Q: Does insurance cover tirzepatide for weight loss? A: Coverage varies widely. Many commercial plans cover Mounjaro for type 2 diabetes but exclude weight-loss use; some now cover Zepbound for obesity. With a covered commercial plan, the Lilly savings card can lower the cost to about $25/month. Starting July 1, 2026, the temporary Medicare GLP-1 Bridge offers eligible Part D beneficiaries the Zepbound KwikPen for a $50 copay. People with Medicare, Medicaid, TRICARE, or VA benefits generally cannot use manufacturer savings cards. Check your specific plan's formulary and prior-authorization rules with your provider.

Q: Is the LillyDirect self-pay vial real, FDA-approved tirzepatide? A: Yes. LillyDirect single-dose vials are brand-name Zepbound (tirzepatide) sold directly by Eli Lilly, the manufacturer, and are FDA-approved. They differ from prefilled pens in that they are drawn up with a separate syringe, which is why they cost less. They are not compounded copies. A valid prescription is required, and the lower pricing on higher doses depends on staying within the Self Pay Journey Program refill window. Confirm current terms and whether self-administration is appropriate for you with your healthcare provider.

Q: Will tirzepatide get cheaper after it goes generic? A: Not soon. Tirzepatide is under patent protection, and no generic is available in 2026, so meaningful generic price competition is years away. Near-term cost relief is coming instead from manufacturer programs (LillyDirect self-pay vials, savings cards) and the temporary Medicare GLP-1 Bridge rather than generics. Compounded copies are not generics and are now legally restricted. For the latest pricing, check LillyDirect and your insurer directly, and discuss options with your provider.

References

1. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. PMID: 40353578. DOI: 10.1056/NEJMoa2416394.
2. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (tirzepatide shortage resolved; 503A enforcement discretion ended Feb 18, 2025; 503B ended Mar 19, 2025). FDA Drug Alerts and Statements, 2025. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
3. U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. FDA Press Announcements, April 30, 2026. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
4. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar, 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
5. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge ($50 copay per 30-day supply; July 1, 2026 – December 31, 2027). CMS, 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
6. Eli Lilly and Company. Lilly lowers the price of Zepbound (tirzepatide) single-dose vials (2.5 mg $299; 5 mg $399; 7.5–15 mg $449 under the Self Pay Journey Program, effective Feb 23, 2026; non-program prices $499 for 7.5 mg and $699 for 10/12.5/15 mg). Lilly Investor News, December 1, 2025. https://investor.lilly.com/news-releases/news-release-details/lilly-lowers-price-zepboundr-tirzepatide-single-dose-vials